The ADOPT-PGx study examined the impact of genotype-guided opioid prescribing on postoperative pain management. Results from the study were recently published in JAMA Network Open, accompanied by an invited commentary reflecting on the findings and their implications for pharmacogenetics in clinical care.

ADOPT-PGx is a pragmatic, randomized clinical trial designed to evaluate whether CYP2D6-guided opioid prescribing improves pain outcomes following surgery compared with usual care. The study was conducted in real-world clinical settings to assess the feasibility and effectiveness of pharmacogenetic implementation at scale.

The primary outcome focused on postoperative pain control, with secondary outcomes examining prescribing patterns and opioid use. While genotype-guided prescribing influenced medication selection, the study found no significant improvement in pain outcomes, underscoring the complexity of acute pain as a multifactorial clinical phenotype.

The invited commentary places these findings in broader context, highlighting both the promise and current limitations of single-gene pharmacogenetic approaches for pain management and emphasizing the need for more integrated strategies to support personalized care.

Read the publication here.

Read the invited commentary here.